Cns Pharmaceuticals Stock Performance
| CNSP Stock | USD 2.48 0.22 9.73% |
The firm shows a Beta (market volatility) of 0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cns Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cns Pharmaceuticals is expected to be smaller as well. At this point, Cns Pharmaceuticals has a negative expected return of -0.79%. Please make sure to confirm Cns Pharmaceuticals' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Cns Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Cns Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 9.73 | Five Day Return 6.44 | Year To Date Return (57.61) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:50 | Last Split Date 2024-06-05 |
1 | CNS Pharmaceuticals to Host Virtual Analyst Investor Day on December 11, 2024 | 12/05/2024 |
2 | CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - TipRanks | 01/03/2025 |
3 | CNS Pharmaceuticals, Inc. Sees Large Decrease in Short Interest | 01/28/2025 |
4 | CNSP stock touches 52-week low at 0.09 amid sharp decline - MSN | 02/11/2025 |
5 | Acquisition by Gumulka Jerzy of 17500 shares of Cns Pharmaceuticals subject to Rule 16b-3 | 02/14/2025 |
6 | CNS Pharmaceuticals, Inc. Participates in the Virtual Investor Top 5 for 25 On-Demand Conference | 02/19/2025 |
7 | CNS Pharmaceuticals to implement 1-for-50 reverse stock split - MSN | 02/25/2025 |
8 | Acquisition by Mahery Amy of 17500 shares of Cns Pharmaceuticals at 0.2586 subject to Rule 16b-3 | 02/27/2025 |
9 | Acquisition by Evans Carl Anthony of 33333 shares of Cns Pharmaceuticals at 0.3 subject to Rule 16b-3 | 02/28/2025 |
| Begin Period Cash Flow | 10.1 M |
Cns |
Cns Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 510.00 in Cns Pharmaceuticals on December 6, 2024 and sell it today you would lose (262.00) from holding Cns Pharmaceuticals or give up 51.37% of portfolio value over 90 days. Cns Pharmaceuticals is currently does not generate positive expected returns and assumes 8.7098% risk (volatility on return distribution) over the 90 days horizon. In different words, 77% of stocks are less volatile than Cns, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cns Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cns Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cns Pharmaceuticals, and traders can use it to determine the average amount a Cns Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0911
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CNSP |
Estimated Market Risk
| 8.71 actual daily | 77 77% of assets are less volatile |
Expected Return
| -0.79 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cns Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cns Pharmaceuticals by adding Cns Pharmaceuticals to a well-diversified portfolio.
Cns Pharmaceuticals Fundamentals Growth
Cns Stock prices reflect investors' perceptions of the future prospects and financial health of Cns Pharmaceuticals, and Cns Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cns Stock performance.
| Return On Equity | -10.19 | ||||
| Return On Asset | -2.24 | ||||
| Current Valuation | (3.22 M) | ||||
| Shares Outstanding | 40.75 M | ||||
| Price To Earning | (13.70) X | ||||
| Price To Book | 1.11 X | ||||
| EBITDA | (18.86 M) | ||||
| Net Income | (18.85 M) | ||||
| Cash And Equivalents | 8.96 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 300.81 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.34 X | ||||
| Book Value Per Share | (2.98) X | ||||
| Cash Flow From Operations | (14.14 M) | ||||
| Earnings Per Share | (352.97) X | ||||
| Market Capitalization | 5.28 M | ||||
| Total Asset | 1.7 M | ||||
| Retained Earnings | (69.57 M) | ||||
| Working Capital | (4.54 M) | ||||
| Current Asset | 6.61 M | ||||
| Current Liabilities | 488.66 K | ||||
About Cns Pharmaceuticals Performance
Assessing Cns Pharmaceuticals' fundamental ratios provides investors with valuable insights into Cns Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cns Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (12.75) | (12.11) | |
| Return On Capital Employed | 4.89 | 5.14 | |
| Return On Assets | (12.75) | (12.11) | |
| Return On Equity | 4.89 | 3.37 |
Things to note about Cns Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cns Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cns Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cns Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cns Pharmaceuticals has high historical volatility and very poor performance | |
| Cns Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cns Pharmaceuticals currently holds about 8.96 M in cash with (14.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Cns Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: CNS Pharmaceuticals to implement 1-for-50 reverse stock split - MSN |
- Analyzing Cns Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cns Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cns Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cns Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cns Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cns Pharmaceuticals' stock. These opinions can provide insight into Cns Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.